Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
ID: 351878Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $250K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351878

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-122.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-122. This initiative aims to support research that significantly advances cancer control and population sciences, focusing on areas such as epidemiology, statistical methods, digital health, and healthcare delivery. The program is particularly designed to encourage applications from early-stage investigators and historically underrepresented groups, with proposals eligible for funding up to $250,000 per year for a maximum of five years. Interested applicants should note that the application due date is June 5, 2024, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-122.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-122-Full-Announcement.html
    PAR-24-122.html
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), has announced a funding opportunity titled "Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-122. This initiative aims to promote research that significantly enhances cancer control through various scientific domains, including epidemiology, statistical methods, digital health, and healthcare delivery. The funding targets early-stage investigators (ESIs) to diversify and expand the applicant pool. Key application dates include: - Open Date: May 5, 2024 - Application Due Date: June 5, 2024 - Expiration Date: November 6, 2024 Proposals can request up to $250,000 per year and up to five years of project duration. Eligible applicants include diverse institutions, non-profits, and for-profit entities, encouraging participation from historically underrepresented groups. Research areas of interest include behavioral studies, genomic epidemiology, healthcare practices, and digital health technologies aimed at improving cancer prevention and survivorship. Applications must conform to strict NIH policies and submission guidelines to ensure compliance and effective use of funds. The overall goal is to drive progress in cancer research and healthcare delivery, ultimately improving outcomes for patients.
    Similar Opportunities
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)." This initiative aims to support research projects that explore innovative cancer communication strategies across three key areas: the development of new surveillance methods, the creation of rapid intervention strategies, and the formulation of multilevel communication models that highlight bidirectional influences. The opportunity is particularly relevant in the context of enhancing cancer prevention and control efforts in an increasingly digital landscape, addressing challenges such as misinformation and health disparities. Interested applicants can apply for funding up to $500,000 per year, with applications due by September 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-164.html.